Amicus Therapeutics (FOLD) : 7 analysts are covering Amicus Therapeutics (FOLD) and their average rating on the stock is 1.29, which is read as a Strong Buy. 6 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Amicus Therapeutics (FOLD) : The most positive equity analysts on Amicus Therapeutics (FOLD) expects the shares to touch $19, whereas, the least positive believes that the stock will trade at $9 in the short term. The company is covered by 7 Wall Street Brokerage Firms. The average price target for shares are $14 with an expected fluctuation of $3.83 from the mean.
Amicus Therapeutics (NASDAQ:FOLD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $5.50 and $5.42 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $5.69. The buying momentum continued till the end and the stock did not give up its gains. It closed at $5.68, notching a gain of 1.79% for the day. The total traded volume was 1,327,643 . The stock had closed at $5.58 on the previous day.
Also, Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD). Bank of America has a Buy rating on the shares. As per the latest report, the brokerage house announces the price target to $10 per share. The rating by the firm was issued on May 18, 2016. The company shares have dropped -59.48% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $18.83 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $6.37 and the 200 Day Moving Average price is recorded at $7.17.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.